CorMedix Inc. — Regulatory Filings 2018

May 29, 2018

style header

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 29, 2018

CORMEDIX INC.
(Exact
Name of Registrant as Specified in Charter)

Delaware	001-34673	20-5894890
(State
or Other Jurisdictionof Incorporation)	(CommissionFile
Number)	(IRS
EmployerIdentification No.)

| 400 Connell Drive, Suite 5000, Berkeley Heights,
NJ | 07922 |
| --- | --- |
| (Address
of Principal Executive Offices) | (Zip
Code) |

Registrant’s Telephone Number, Including Area Code: (908) 517-9500

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

style footer

page break

Item 8.01. Other Events.

On May 29, 2018, we issued a press release to report the progress on our Lock-It 100 trial data review and to announce the appointment of Paul Chew as a Consultant Advisor CMO.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

anchor Item 9.01. Financial Statements and Exhibits .

(d)

Exhibits

Exhibit No.	Description
99.1	Press
release dated May 29, 2018.

2

page break

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| /s/ Robert
W. Cook |
| --- |
| Name: Robert W.
Cook |
| Title: Chief
Financial Officer |

3

page break